Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Clinical Trials

1 actively recruiting trial across 1 location

Also known as: CIMAvax EGF, CIMAvax Epidermal Growth Factor Vaccine, CIMAvax-EGF, Center of Molecular Immunology (CIMA) Epidermal Growth Factor (EGF) Vaccine, Center of Molecular Immunology Epidermal Growth Factor Vaccine +3 more

Pipeline

Early 1: 1

Top Sponsors

Roswell Park Cancer Institute1

Indications

Chronic Obstructive Pulmonary Disease1
Pneumonia1
Stage IIB Lung Cancer AJCC v81
Stage IIA Lung Cancer AJCC v81
Stage II Lung Cancer AJCC v81

Buffalo, New York1 trial

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Roswell Park Cancer Institute

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.